Celldex Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Celldex Therapeutics, Inc. (CLDX) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $48.97 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-02-25
- Celldex Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $48.97M.
- Celldex Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was -$27.63M, a 179.81% decline from fiscal 2023.
- Celldex Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was $34.62M, a 238.45% increase from fiscal 2022.
- Celldex Therapeutics, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2022 was $10.23M, a 8.33% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month |
|---|---|
| 2025-12-31 | $48.97M 10-K · filed 2026-02-25 |
| 2024-12-31 | -$27.63M 10-K · filed 2026-02-25 |
| 2023-12-31 | $34.62M 10-K · filed 2026-02-25 |
| 2022-12-31 | $10.23M 10-K · filed 2025-02-27 |
| 2021-12-31 | $11.16M 10-K · filed 2024-02-26 |
| 2020-12-31 | $956.00K 10-K · filed 2023-02-28 |
| 2019-12-31 | -$2.93M 10-K · filed 2022-02-28 |
| 2018-12-31 | $28.81M 10-K · filed 2021-03-29 |
| 2017-12-31 | -$66.29M 10-K · filed 2020-03-26 |
| 2016-12-31 | $53.91M 10-K · filed 2019-03-07 |
| 2015-12-31 | $57.09M 10-K · filed 2018-03-07 |
| 2014-12-31 | $48.56M 10-K · filed 2017-03-14 |
| 2013-12-31 | $35.76M 10-K/A · filed 2016-02-25 |
| 2012-12-31 | $22.20M 10-K · filed 2015-02-24 |
| 2011-12-31 | $19.01M 10-K · filed 2014-03-03 |
| 2010-12-31 | -$11.53M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |